Celldex Therapeutics, Inc. Equity Securities, FV-NI, Cost
Celldex Therapeutics, Inc. (CLDX) had Equity Securities, FV-NI, Cost of $1.80 million as of 2018-12-31, per its 10-K filed 2022-02-28.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecuritiesFvNiCost · last filed 2022-02-28
- 2018-12-31: Equity Securities, FV-NI, Cost $1.80M.
| Period end | Equity Securities, FV-NI, Cost |
|---|---|
| 2018-12-31 | $1.80M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |